IGBA biosimilar medicines slide decks

The era of biological medicines
Since their first use in the 1980s, biological medicines (including biosimilar medicines) have grown to become an indispensable tool in modern medicine. Worldwide, millions of patients have already benefited from approved biological medicines, but what exactly are they, and how are they produced?


Biological medicines ― the major social and economic challenges
The global spend on pharmaceuticals continues to increase. The use of biological medicines offers new treatment choices to patients, but at a high financial cost. What are the challenges faced by payers and physicians in preserving access to biological medicines within a financially constrained healthcare system?


Biosimilar medicines — rising to the cost challenge
Addressing the rising cost of biological medicines has become a priority for governments and healthcare systems around the globe.
Biosimilar medicines are providing more cost-effective biological treatments, but what are biosimilar medicines, and how do they meet this challenge?


Biosimilar medicines — a commitment to scientific excellence
With biosimilar medicines, patients and healthcare providers benefit from high quality and efficacious therapeutic alternatives.
But how are biosimilar medicines developed, and how is their efficacy and safety ensured?


The benefits of biosimilar medicines
Biosimilar medicines have demonstrated similarity with reference biologicals in terms of structure, function, safety and efficacy, but what are their benefits?


Building on the experience and success of biosimilar medicines
Biosimilar medicines are increasingly becoming an integral part of modern healthcare systems, so what does the future hold?


If you wish to use any part of this slide deck, please contact us at igba@igbamedicines.org. We would be happy to share this with you.

What are the key messages of the ESMO 2017 symposium?

Biosimilars — Can the dream of affordable cancer care come true?

A Clinician´s Guide to Biosimilars in Oncology: Understanding the Science of Extrapolation and Interchangeability

Biosimilars in the EU – Information guide for healthcare professionals

Q&A for patients – Biosimilar medicines explained

The European Commission has published improved information for patients on biosimilar medicines. The Q&A are available in 7 languages (English, French, German, Italian, Polish, Portuguese and Spanish) offering patients access to unbiased and reliable information.

Biological medicines (including biosimilars) come from living organisms (cells) that have been modified using biotechnology.

A biosimilar medicine is developed to be highly similar to an existing biological medicine. They have a great importance in the treatment of severe diseases such as cancers.

Biosimilars have significant potential to create competition in the biological medicine market and provide patients with broader affordable access to state of the art medicines.

The Q&A document was first published in 2013 as part of the consensus information paper, ‘What you need to know about biosimilar medicinal products‘. The main goal of this revision is to provide patients with information in language that is easy to understand, despite the complexity of the concept.

The next stakeholder workshop organised by the Commission on the uptake of biosimilar medicines in the EU is on 5 May 2017.

What I need to know about Biosimilar Medicines – Information for patients  (7 MB)

EAHP satellite on Biosimilar medicines

Maarten Van Baelen – Intro + Niklas Ekman – Biosimilars from the perspective of an EU regulator

Maarten Van Baelen

Niklas Ekman

Arnold Vulto – Biosimilars concerns of prescribers and how to address them as a hospital pharmacist

Arnold Vulto

Paul Cornes – Biosimilars – can we do without them

Paul Cornes

Please find  the report of the satellite symposium held at the EAHP conference here.

What you Need to Know About Biosimilar Medicinal Products

European Commission Consensus Information Document: What you Need to Know About Biosimilar Medicinal Products.

To view the full report, please click here.